GNIPST BULLETIN 2016

04-11-2016

04th November, 2016

Volume No.: 60 Issue No.: 03

Vision
To develop responsible citizens who would be professionally equipped to think globally and act
locally and become reformers of society to meet the challenges of future.
Mission
To impart high quality pharmaceutical science, technology and management education to the budding
professionals and provide the ambience needed for developing requisite skills to make a mark of
excellence in Education, Research, Business , Industry and achieve highest personal standards.
Contents
Message from PRINCIPAL
Editorial board
Historical article
News Update
Knowledge based Article
Disease Related Breaking News
Upcoming Events
Drugs Update
Campus News
Students Section
Editors Note

Archive

GNIPST Photo Gallery

For your comments/contribution

OR For Back-Issues,
mailto:gnipstbulletin@gmail.com

GURU NANAK INSTITUTE OF PHARMACEUTICAL

SCIENCE AND TECHNOLOGY
Website: http://gnipst.ac.in

04-11-2016

MESSAGE FROM PRINCIPAL

"It can happen. It does happen.

But it can't happen if you quit." Lauren Dane.

We are what we repeatedly do.

Excellence then is not an act, but a habit. Aristotle

It gives me immense pleasure to pen a few words for our e-bulletin. At the onset I would like to thank the
last years editors and congratulate the newly selected editors for the current year.
Our first consideration is always in the best interest of the students. Our goal is to promote academic
excellence and continuous improvement.
I believe that excellence in education is aided by creating a learning environment in which all learners are
supported in maximizing their potential and talents. Education needs to focus on personalized learning
and instruction, while promoting an education system that is impartial, universally accessible, and meeting
the needs of all students.
It is of paramount importance that our learners have sufficient motivation and encouragement in order to
achieve their aims. We are all very proud of you, our students, and your accomplishments and look
forward to watching as you put your mark on the profession in the years ahead.
The call of the time is to progress, not merely to move ahead. Our progressive Management is looking
forward and wants our Institute to flourish as a Post Graduate Institute of Excellence. Steps are taken in
this direction and fruits of these efforts will be received by our students in the near future. Our Teachers
are committed and dedicated for the development of the institution by imparting their knowledge and play
the role of facilitator as well as role model to our students.
The Pharmacy profession is thriving with a multitude of possibilities, opportunities and positive
challenges. At Guru Nanak Institute of Pharmaceutical Science and Technology, our focus is on holistic
needs of our students.
I am confident that the students of GNIPST will recognize all the possibilities, take full advantage of the
opportunities and meet the challenges with purpose and determination.
Excellence in Education is not a final destination, it is a continuous walk. I welcome you to join us on
this path.
My best wishes to all.
Dr. A. Sengupta

Click here to go at the top

1

04-11-2016

EDITORIAL BOARD
CHIEF EDITOR
EDITOR
ASSOCIATE EDITOR

DR. ABHIJIT SENGUPTA

MS. JEENATARA BEGUM
MR.
DIPANJAN
MANDAL

HISTORICAL ARTICLE

Ibn Rushd
1126-1198

Early Life:
Abu Walid Mohammad Ibn Rushd born in 1128 C.E. in Cordova
has been held as one of the greatest thinkers and scientists of the
history. A product of twelfth-century Islamic Spain, he set out to
integrate Aristotelian philosophy with Islamic thought. A common
theme throughout his writings is that there is no
inappropriateness between religion and philosophy when both are
properly understood.
His contributions to philosophy took many forms, ranging from
his detailed commentaries on Aristotle, his defence of philosophy
against the attacks of those who condemned it as different to Islam
and his construction of a form of Aristotelianism which cleansed it,
as far as was possible at the time, of, Neoplatonic influences.
Contributions and Achievements:
Ibn Rushds education followed a traditional path, beginning with
studies in Hadith, linguistics, jurisprudence and scholastic
theology. Throughout his life he wrote extensively on Philosophy
and Religion, attributes of God, origin of the universe,
Metaphysics and Psychology but he excelled in philosophy and
jurisprudence and was nicknamed the jurisprudent philosopher.
The role of the philosopher in the state was a topic of continual
interest for Ibn Rushd.
His thought is genuinely creative and highly controversial,
producing powerful arguments that were to puzzle his
Click here to go at the top
2

04-11-2016

philosophical successors in the Jewish and Christian worlds. He

seems to argue that there are two forms of truth, a religious form
and a philosophical form, and that it does not matter if they point
in different directions. He also appears to be doubtful about the
possibility of personal immortality or of Gods being able to know
that particular events have taken place. There is much in his work
also which suggests that religion is inferior to philosophy as a
means of attaining knowledge, and that the understanding of
religion which ordinary believers can have is very different and
impoverished when compared with that available to the
philosopher.
In philosophy, his most important work Tuhafut al-Tuhafut was
written in response to Al-Ghazalis work. Ibn Rushd was
criticized by many Muslim scholars for this book, which,
nevertheless, had a deep influence on European thought, at least
until the beginning of modern philosophy and experimental
science. His views on fate were that man is neither in full control
of his destiny nor is it fully predetermined for him. Al Rushds
longest commentary was, in fact, an original contribution as it was
largely based on his analysis including interpretation of Quranic
concepts. Ibn Rushds summary the opinions (fatwa) of previous
Islamic jurists on a variety of issues has continued to influence
Islamic scholars to the present day, notably Javed Ahmad Ghamidi.
At the age of 25, Ibn Rushd conducted astronomical observations
in Morocco, during which he discovered a previously unobserved
star. He was also of the view that the Moon is opaque and obscure,
and has some parts which are thicker than others, with the thicker
parts receiving more light from the Sun than the thinner parts of
the Moon. He also gave one of the first descriptions on sunspots.
Ibn Rushd also made remarkable contributions in medicine. In
medicine his well-known book Kitab al-Kulyat fi al-Tibb was
written before 1162 A.D Its Latin translation was known as
Colliget. In it Ibn Rushd has thrown light on various aspects of
medicine, including the diagnoses, cure and prevention of diseases
and several original observations of him.
Click here to go at the top
3

04-11-2016

He wrote at least 67 original works, which included 28 works on

philosophy, 20 on medicine, 8 on law, 5 on theology, and 4 on
grammar, in addition to his commentaries on most of Aristotles
works and his commentary on Platos The Republic. A careful
examination of his works reveals that Ibn Rushd (Averroes) was a
deeply Islamic man. As an example, we find in his writing, Anyone
who studies anatomy will increase his faith in the omnipotence
and oneness of God the Almighty. He believed that true happiness
for man can surely be achieved through mental and psychological
health, and people cannot enjoy psychological health unless they
follow ways that lead to happiness in the hereafter, and unless they
believe in God and His oneness.
Death:
Ibn Rushd died in Marakesh in 1198 where he was buried. Three
months later, his body was moved to Qurtuba, the tribune of his
thought. It leaves no room for any doubt about the important
influence that the Muslim Philosopher had on the greatest of all
Catholic theologians.

NEWS UPDATE

Rubella virus persists after vaccination in some

patients with immunodeficiency disorders: (04th
November, 2016)

Some patients with rare primary immunodeficiency disorders may

be at risk for infection by rubella virus, and possibly serious skin
inflammation, after receiving the rubella vaccine, usually
administered as part of the measles-mumps-rubella (MMR)
vaccine. Although the vaccine for rubella (German measles) has an
established record of safety and effectiveness in the general
population, patients with severe deficiencies in their immune
defenses may be susceptible to side effects from the vaccine, say
researchers.

Click here to go at the top

4

04-11-2016

Tumor cells in blood samples could predict

prostate cancer spread: (04th November, 2016)
Researchers have found a group of circulating tumor cells in
prostate cancer patient blood samples that are linked to the spread
of the disease, according to new research.

Scientists identify genetic markers of resistance

to frontline malaria drug that could help control
outbreaks: (04th November, 2016)

Scientists have identified genetic markers associated with

resistance to the one of the most commonly used malaria drugs in
Southeast Asia. The findings of two independent studies from
Cambodia could be used to help track and contain the spread of
drug-resistant disease in the region.

Stem cell therapy appears to have

treatment effect: (03rd November, 2016)

TBI

Results of a cellular therapy clinical trial for traumatic brain injury

(TBI) using a patients own stem cells showed that the therapy
appears to dampen the bodys neuroinflammatory response to
trauma and preserve brain tissue, according to researchers.

Researchers describe method to study real time

cancer invasion: (03rd November, 2016)

A research team has described the steps, in both written and video
format, that allow cancer investigators to track, in real time, cancer
cell invasion and metastasis in transparent zebrafish embryos.
Using these fish models, researchers can find answers to cancer
questions in one to three days instead of months for the typical
mouse model.

Click here to go at the top

5

04-11-2016

Scientists advance understanding of how retinal

cells are formed: (03rd November, 2016)

Researchers have identified two genesTbx3 and Pax6that

together are sufficient to start the process of eye development.

Diagnosis
of
Alzheimer's
disease:
antibodies
detect
cerebral
lesions:
November, 2016)

Llama
(03rd

The major challenge facing physicians treating Alzheimer's is the

ability to detect markers of the disease as early as possible. These
markers, located in the brain, are difficult to access, hampering
diagnosis. Using two types of llama antibody capable of crossing
the blood-brain barrier, scientists have developed a non-invasive
approach to reach brain cells in a mouse model of the disease.

Research on pigment production reveals Achilles'

heel for MRSA: (03rd November, 2016)

A molecular explanation has been discovered for how the

bacterium behind the super bug MRSA produces a red pigment
that is crucial for its rapid growth.

Scientists identify bacterial genes that could

lessen severity of malaria: (03rd
November,
2016)
A set of bacterial genes has been identified that may help
researchers find ways to lessen the severity of the disease malaria.
This findings could also aid the research of fellow scientists
working in malaria-stricken regions around the world.
For detail mail to editor

Click here to go at the top

6

04-11-2016

KNOWLEDGE BASED ARTICLE

Accelerated approval to new treatment for

advanced soft tissue sarcoma
The grant is for accelerated approval to Lartruvo (olaratumab)
with doxorubicin to treat adults with certain types of soft tissue
sarcoma (STS), which are cancers that develop in muscles, fat,
tendons or other soft tissues. Lartruvo is approved for use with the
FDA-approved chemotherapy drug doxorubicin for the treatment
of patients with STS who cannot be cured with radiation or
surgery and who have a type of STS for which an anthracycline
(chemotherapy) is an appropriate treatment.
For these patients, Lartruvo, added to doxorubicin, provides a
new treatment option, said Richard Pazdur, M.D., director of the
Office of Hematology and Oncology Products in the FDAs Center
for Drug Evaluation and Research and acting director of the FDAs
Oncology Center of Excellence. This is the first new therapy
approved by the FDA for the initial treatment of soft tissue
sarcoma since doxorubicins approval more than 40 years ago.
The National Cancer Institute estimates that 12,310 new cases of
STS and nearly 5,000 deaths are likely to occur from the disease in
2016. The most common treatment for STS that cannot be removed
by surgery is treatment with doxorubicin alone or with other
drugs. STS includes a wide variety of tumors arising in the muscle,
fat, blood vessels, nerves, tendons or the lining of the joints.
Lartruvo is a platelet-derived growth factor (PDGF) receptoralpha blocking antibody. When stimulated, PDGF receptors cause
tumor growth. Lartruvo works by blocking these receptors, which
may help slow or stop tumor growth.
The safety and efficacy of Lartruvo were studied in a randomized
clinical trial involving 133 patients with more than 25 different
subtypes of metastatic STS. Patients received either Lartruvo with
doxorubicin or doxorubicin alone. This trial measured the length
of time patients lived after treatment (overall survival), the length
Click here to go at the top
7

04-11-2016

of time tumors did not grow after treatment (progression-free

survival) and the percentage of patients who experienced
shrinkage of their tumors (overall response rate). Patients in this
trial who received Lartruvo with doxorubicin had a statistically
significant improvement in overall survival: the median survival
was 26.5 months compared to 14.7 months for patients who
received doxorubicin alone. Patients who received Lartruvo with
doxorubicin had a median progression-free survival of 8.2 months
compared to 4.4 months for patients who received doxorubicin
alone. Tumor shrinkage was 18.2 percent for patients who received
Lartruvo with doxorubicin and 7.5 percent for those who received
doxorubicin alone.
Lartruvo has serious risks including infusion-related reactions and
embryo-fetal harm. Infusion-related reactions include low blood
pressure, fever, chills and rash. The most common side effects of
treatment with Lartruvo are nausea, fatigue, low levels of white
blood cells (neutropenia), musculoskeletal pain, inflammation of
the mucous membranes (mucositis), hair loss (alopecia), vomiting,
diarrhea, decreased appetite, abdominal pain, nerve damage
(neuropathy) and headache.
The
FDA
granted
the
Lartruvo
application fast
track designation, breakthrough therapy designation and priority
review status because preliminary clinical evidence indicated that
it may offer a substantial improvement in effectiveness in the
treatment of a serious or life-threatening disease or condition. The
FDA is approving Lartruvo under the agencys accelerated
approval program, which allows approval of a drug to treat a
serious or life-threatening disease or condition based on clinical
data showing the drug has an effect on a surrogate endpoint that is
reasonably likely to predict clinical benefit. The sponsor is
conducting a larger study, which is currently underway, to further
explore the effectiveness of Lartruvo across the multiple subtypes
of STS.
Lartruvo also received orphan drug designation, which provides
incentives such as tax credits, user fee waivers and eligibility for
Click here to go at the top
8

04-11-2016

exclusivity to assist and encourage the development of drugs

intended to treat rare diseases.
Jeenatara Begum
Assistant Professor
GNIPST

DISEASE RELATED BREAKING NEWS

Middle East respiratory syndrome coronavirus

(MERS-CoV) Saudi Arabia: (31st
October,
2016)

Between 16 September and 10 October 2016 the National IHR

Focal Point of Saudi Arabia seven (7) additional cases of Middle
East Respiratory Syndrome (MERS) including one (1) fatal case.
Read more

UPCOMING EVENTS

IEEE forum-International conference on medical biological and

pharmaceutical sciences (ICMBPS) will be held on 5th November
2016 at Mumbai, Maharashtra, India.
5th Biennial conference DDNPTM-2016 will be held on 18th to 20th
November, 2016 at National Institute of Pharmaceutical Education
and Research (NIPER) SAS Nagar, Mohali, Punjab-160062.

DRUGS UPDATES

FDA Approves Expanded Use of Enbrel (etanercept)

to Treat Children with Chronic Moderate-ToSevere Plaque Psoriasis: (04th November, 2016)
Amgen (NASDAQ:AMGN) announced that the U.S. Food and
Drug Administration (FDA) has approved the supplemental
Biologics License Application (sBLA) for the expanded use
of Enbrel (etanercept), making it the first and only systemic
Click here to go at the top
9

04-11-2016

therapy to treat pediatric patients (ages 4-17) with chronic

moderate-to-severe plaque psoriasis.
Read more

CAMPUS NEWS
International seminar 2016:
International seminar on Global Advancement in Pharmaceutical
research and startup organized by GNIPST in collaboration with
IPGA was held on 22nd October, 2016 at GNIPST auditorium.
NBA visit:
The experts of National Board of Accreditation or NBA will be
going to visit GNIPST on 24th September and 25th September,
2016.
Freshers welcome programme:
On 12th September GNIPST organized the Freshers welcome
programme Kulrav 2k16.
GNIPST Football Match 2016:
On 31st August and 1st September GNIPST sports club organized a
football match. The winner of the football match was B.Pharm 3rd
year.
Recent Trends in Pharmaceutical Research:
A Science Awareness Programme comprising of seminar on
Recent Trends in Pharmaceutical Research was organized by
GNIPST in collaboration with National Academy of Science India
(NASI) on 30th august, 2016 from 2 pm to 4.30 pm at GNIPST
auditorium. Plantation programme was also organized by Eco club.
Dr. Hemanta Kumar Majumder, gave his valuable lecture on
Modern Biology & its Evolution and Dr. Pijush K Das delivered
his lecture on Site specific Drug Targeting Magic Bullet
approach.
Click here to go at the top
10

04-11-2016

World Photography Day celebration:

On 19th August 2016 GNIPST celebrated World Photography Day
at Dakhineswar.
Friendly Football Match:
On 15th August 2016 GNIPST organised a friendly football match
with Alumni members.
Farewell 2016:
On 25th May 2016 GNIPST celebrated the farewell programme for
the final year students. Best of luck to all final year students for
their future life.
ALUMNI MEMBERS 2016:
Congratulations to new Alumni Members of GNIPST.
Placement Record 2016:
SL
NO

COMPANY NAME

NUMBER OF
NUMBER OF
STUDENT
STUDENT
APPEARED/APPLIED SELECTED
64
7

JOB
PROFILE

DR. LAL PATH LAB

APOLLO
PHARMACY

36

25

ABBOTT INDIA

74

03

HETERO DRUGS

18

Production,
QC and QA

ERIS LIFE SCIENCES

01

18 (Waiting
for final
interview)
01 (Joined)

JUPITER
PHARMACEUTICALS

05

01 (Joined)

Production,
QC and QA

GOVT PHARMACIST

4 (Joined)

Hospital
Pharmacist

ALCHEMIST EYE
HOSPITAL

2 (Waiting for
final
interview)

Hospital
Pharmacist

Sales,
Marketing and
office assistant
Hospital and
retail chain
pharmacist
Sales and
Marketing

Sales and
Marketing

Click here to go at the top

11

04-11-2016
9

21

21

Community
Pharmacist

10

OPTIVAL HEALTH
SOLUTIONS PVT.
LTD. (MEDPLUS)
NESTLE INDIA LTD

08

02

11

LUPIN

01

01

Nutrition
Officer
Trainee
Sales and
Marketing

12

GSK
PHARMACEUTICAL
LTD
OAK
PHARMACEUTICAL

05

02 (1 of them
already joined)

Sales and
Marketing

06

02 (Joined)

Sales and
Marketing

13

IPA Bengal Pharma & Healthcare trust scholarship 2016:

Congratulations to Rudradip Das, student of B.Pharm 3rd year has

been awarded IPA Bengal Pharma & Healthcare trust scholarship
2016.
Accreditation by NAAC:
SL.
NAME
OF
STATE
CGPA(out
GRADE
NO.
THE
of scale 4)
INSTITUTE
01
Guru
Nanak
West
2.70
B
Institute
of
Bengal
Pharmaceutical
Science
And
Technology,
Kolkata-700114

GPAT 2016 Result:

The following B.Pharm. final year students have qualified, GPAT2016. We congratulate them all.
Aishika Datta
Mainak Chatterjee
Indira Saha
Priyanka De
Click here to go at the top
12

04-11-2016

Aheli Mukherjee
Soumya Guha
Debanjana Das
Debalina Datta
Evana Patra
Himadrija Chatterjee
IRIS 2016:
GNIPST organized colllege fest IRIS 2016 from 11th to 13th March,
2016.
Result of different events:
Intracollege Quiz competition:
1st: Arani Roy and Dipayan Nath
2nd: Bhaskar Singha and Pratik Nandi
Intracollege Painting competition:
1st: Swagata Paul
2nd: Aviraj Pathak
3rd: Dippyoman Guha
Group Dance Competition:
Karma Group
Intercollege Solo Dance Competition:
1st : Monodipa Ghosh
2nd: Aditya Paul (NIT)
Antaksari Competition:
1st: Sunanda and Aparupa
2nd: Meghna and Joyita
3rd: Arpita and Pami
Intercollege Solo Singing Competition:
1st: Arpita Sarkar
2nd: Arvind Raj (Sudhir Chandra College)
3rd: Priyam Mondal (Supreme College)
Intercollege Band Competition:
Click here to go at the top
13

04-11-2016

1st: D Errors
2nd: Mukti
3rd: GNIPST band
Fashion:
Best Male: Md. Nadeem Shah
Best Female: Sweta
Best Couple: Md. Nadeem Shah and Susmita Kar
Blood donation Camp 2016:
On 4th March 2016 Social Service club and Alumni Association
of GNIPST organized a Blood donation camp in association with
Association of voluntary Blood Donars, West Bengal.
Reminiscence & 1st Alumni meet 2016:
On 28th February 2016 GNIPST organized the Reunion programme
Reminiscence & 1st Alumni meet 2016.
National Assessment and Accreditation Council (NAAC):
A NAAC peer team completed a three-day inspection (17th
February to 19th February, 2016) of GNIPST to evaluate its
academic credibility and infrastructure on Friday.
Saraswati Puja 2016:
On 13th February 2016 the students of GNIPST celebrated
Saraswati Puja at GNIPST campus.

STUDENTS SECTION
WHO CAN ANS WER FIRS T????
Which lymphatic disease is named after thisn
scientist?

Click here to go at the top

14

04-11-2016
Answer of Previous Issues Image:
Dorothy Crowfoot Hodgkin

Send

your
thoughts/
Quiz/Puzzles/games/write-ups or any other
contributions for Students Section& answers
of this Section at gnipstbulletin@gmail.com
EDITORS NOTE
It is a great pleasure for me to publish the 3rd issue of 60th Volume
of GNIPST BULLETIN. All the followers of GNIPST BULLETIN
are able to avail the bulletin through facebook account GNIPST
bulletin I am very much thankful to all the GNIPST members and
readers who are giving their valuable comments, encouragements
and supports. I am also thankful to Dr. Abhijit Sengupta, Director
of GNIPST for his valuable advice and encouragement. Special
thanks to Dr. Prerona Saha, Mr. Debabrata Ghosh Dastidar
and Mr. Soumya Bhattacharya for their kind co-operation and
technical supports. Thank you Mr. Soumya Bhattacharya for the
questionnaires of the student section. An important part of the
improvement of the bulletin is the contribution of the readers. You
are invited to send in your write ups, notes, critiques or any kind of
contribution for the forthcoming special and regular issue.
ARCHIVE
OTHERS:
AICTE has sanctioned a release of grant under Research
Promotion Scheme (RPS) during the financial year 2012-13to
GNIPST as per the details below:
a. Beneficiary Institution: Guru Nanak Institution of Pharmaceutical
Science & Technology.
Click here to go at the top
15

04-11-2016

b. Principal Investigator: Dr. LopamudraDutta.

c. Grant-in-aid sanctioned:Rs. 16,25000/- only
d. Approved duration: 3 years
e. Title of the project: Screening and identification of potential
medicinal plant of Purulia & Bankura districts of West Bengal
with respect to diseases such as diabetes, rheumatism, Jaundice,
hypertension and developing biotechnological tools for enhancing
bioactive molecules in these plants.

Activity Clubs of GNIPST:

Name of Club
CULTURAL
DEBATE AND EXTEMPORE
ECO
LITERARY AND PAINTING
PHOTOGRAPHY

Member Faculty
Ms. Priyanka Ray
Mr. Soumya Bhattacharya
Ms. Sumana Roy
Ms. Jeenatara Begum
Ms. Sanchari Bhattacharya and
Mr. Abir Koley
SCIENCE AND INNOVATIVE Mr. Samrat Bose
MODELLING
SOCIAL SERVICES
Dr. Asis Bala
SPORTS
Mr. Debabrata GhoshDastidar

Click here to go at the top

16